| Submission declined on 2 February 2024 by DoubleGrazing (talk). The proposed article does not have sufficient content to require an article of its own, but it could be merged into the existing article at Liraglutide. Since anyone can edit Wikipedia, you are welcome to add that information yourself. Thank you.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Saxenda and Liraglutide edit
Saxenda is an injectable medication that is recommended for those patients (adults) who are overweight or suffer from other related diseases such as obesity.
The injection is the injectable presentation for the medication liraglutide, which is used to treat blood sugar disorders in patients, the majority of whom are obese or diabetics.
Liraglutide is a drug that is designed to control and manage sugar levels within an individual, it is used to medicate and help people with type 2 diabetes or obesity.
Obesity edit
Obesity is a chronic illness that has harmed hundreds of people for a long time. It is the buildup of fat within the human body that is detrimental to one's health.
Consequences or Negative effects: edit
Like all medications, this one has consequences or side effects when stopped, even though it has helped a lot of people.
Digestive Problems edit
In the Journal of Endocrinology, Metabolism and Diabetes of South Africa,[9] according to L. Lambert, "During clinical trials, gastrointestinal reactions were the most commonly reported adverse reactions." These consist of constipation, diarrhea, vomiting, and nausea.
Rebound effect / Weight gaining edit
In the Medicine Matters - Diabetes website,[10] they discussed how Bodyweight rebounds after the withdrawal of the medication:
“The researchers found that people who lost the most weight while taking semaglutide tended to then regain the most after stopping it, although they still retained a larger reduction from baseline than participants who had lost less weight during the treatment period.”
The issue with this medication is that,[11] similar to other medicines, it does not work like magic; instead, the effectiveness of the medication depends on how well the person taking it is managing it. Long-term medication effects end, and maintaining your well-being depends entirely on maintaining a regular schedule and leading a balanced, healthy life. After stopping the medication, the rebound effect happens in people who do not follow a healthy diet and routine.
- ^ "Can You Maintain Weight-Loss After Saxenda?". www.ukmeds.co.uk. Retrieved 2 February 2024.
- ^ Goodman, Brenda (5 October 2023). "Researchers link popular weight loss drugs to serious digestive problems for 'hundreds of thousands' worldwide". CNN. Retrieved 1 February 2024.
- ^ Henderson, Laura (23 January 2023). O'Loan, James (ed.). "The Side Effects of Stopping Saxenda | Withdrawal Symptoms". myBMI. Retrieved 1 February 2024.
- ^ McDermid, Eleanor. "Bodyweight rebounds after semaglutide withdrawal". diabetes.medicinematters.com. Retrieved 1 February 2024.
- ^ Romantsova, Tatiana Ivoanova (25 April 2018). "Analog glyukagonopodobnogo peptida-1 liraglutid (Saksenda®): mekhanizm deystviya, effektivnost' v lechenii ozhireniya" Аналог глюкагоноподобного пептида-1 лираглутид (Саксенда®): механизм действия, эффективность в лечении ожирения [Glucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, effectiveness in the treatment of obesity]. Ožirenie i Metabolizm. 15 (1): 3–11. doi:10.14341/omet201813-11. Retrieved 2024-02-01.
- ^ "Prescription Weight-Loss Medicine | Saxenda® (liraglutide) injection 3mg". www.saxenda.com. Retrieved 1 February 2024.
- ^ Nuffer, Wesley A.; Trujillo, Jennifer M. (October 2015). "Liraglutide: A New Option for the Treatment of Obesity". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 35 (10): 926–934. doi:10.1002/phar.1639. PMID 26497479. S2CID 23968739.
- ^ Kelly, Aaron S.; Auerbach, Pernille; Barrientos-Perez, Margarita; Gies, Inge; Hale, Paula M.; Marcus, Claude; Mastrandrea, Lucy D.; Prabhu, Nandana; Arslanian, Silva (28 May 2020). "A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity". New England Journal of Medicine. 382 (22): 2117–2128. doi:10.1056/NEJMoa1916038. ISSN 0028-4793. PMID 32233338.
- ^ Lambert, L (2021). "Focus on Saxenda® solution for injection". Journal of Endocrinology, Metabolism and Diabetes of South Africa. 25.1 (2021): 8–10. doi:10.1056/NEJMoa1916038. PMID 32233338. Retrieved 2 February 2024.
- ^ McDermid, Eleanor (9 May 2022). "Bodyweight rebounds after semaglutide withdrawal". diabetes.medicinematters.com. Retrieved 2 February 2024.
- ^ "»Saxenda - ¿Qué es? - Efecto Rebote - Testimonios" [»Saxenda - What is it? - Rebound Effect - Testimonials] (in Spanish). 2023-10-04. Retrieved 2024-02-02.